Pediatric Hemp-Derived Cannabinoid and Δ9-THC Exposures: A National Poison Data Study.
Table of Contents
- Pediatric Hemp-Derived Cannabinoid and Δ9-THC Exposures: A National Poison Data Study.
- FAQ
- Are hemp-derived cannabinoids more dangerous than Delta-9 THC in pediatric exposures?
- How common are unintentional pediatric cannabis exposures in children under 5?
- What are the most serious complications to watch for in pediatric cannabinoid poisoning?
- Should I treat hemp-derived cannabinoid exposures differently than traditional marijuana exposures?
- What makes hemp-derived cannabinoids potentially more toxic than Delta-9 THC?
- Read next
- FAQ
Pediatric Hemp-Derived Cannabinoid and Δ9-THC Exposures: A National Poison Data Study.
Hemp-derived cannabinoids show higher rates of respiratory depression and hypotension than Delta-9 THC in unintentional pediatric exposures.
This poison control data demonstrates that hemp-derived cannabinoids may pose greater acute cardiovascular and respiratory risks than traditional Delta-9 THC in young children. The findings suggest these newer cannabinoid analogs are not necessarily safer alternatives despite their legal status in many jurisdictions.
Parents and clinicians need to understand that hemp-derived products are not benign and may actually carry higher acute toxicity risks than traditional cannabis edibles. Emergency departments should be prepared for potentially more severe presentations with these newer cannabinoid exposures.
| Study Type | Retrospective Cohort Study |
| Population | Children ≤5 years with single-substance cannabis edible exposures, n=11,836 |
| Intervention | Unintentional ingestion of hemp-derived cannabinoids (Delta-8 THC, Delta-10 THC, THC-O) |
| Comparator | Unintentional ingestion of Delta-9 THC edibles |
| Primary Outcome | Clinical effects, interventions, and outcomes reported to poison control centers |
| Key Finding | Hemp-derived cannabinoids associated with higher respiratory depression (5.9% vs 4.6%) and hypotension (3.87% vs 2.97%) |
| Journal | The Journal of Pediatrics |
| Year | 2025 |
Hemp-derived cannabinoid exposures in young children require vigilant monitoring for respiratory and cardiovascular complications. These products should not be assumed safer than traditional cannabis edibles based on their legal status or marketing.
This study cannot establish causation or explain why hemp-derived cannabinoids appear more toxic—differences could reflect potency, formulation, or reporting bias. The study lacks detailed product analysis or controlled dosing information that would clarify mechanism.
Poison control data relies on caller reporting of product contents, which may be inaccurate. The hemp-derived group is smaller and differences, while statistically significant, are modest in absolute terms and could reflect confounding factors.
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →Hemp-derived cannabinoids present a real and potentially greater acute toxicity risk than Delta-9 THC in pediatric exposures. Clinical vigilance and improved product regulation are warranted while we better understand these compounds’ safety profiles.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Are hemp-derived cannabinoids more dangerous than Delta-9 THC in pediatric exposures?
Yes, this study found that hemp-derived cannabinoids (Δ8-THC, Δ10-THC, THC-O) caused higher rates of respiratory depression (5.9% vs 4.6%) and hypotension (3.87% vs 2.97%) compared to Delta-9 THC exposures. Children exposed to hemp-derived cannabinoids also required vasopressor support nearly three times more frequently than those exposed to traditional Delta-9 THC.
How common are unintentional pediatric cannabis exposures in children under 5?
Based on national poison control data from 2023-2024, there were 11,836 cases of unintentional cannabis edible exposures in children ≤5 years old. The majority (9,667 cases) involved Delta-9 THC products, while 2,169 cases involved hemp-derived cannabinoids, indicating these exposures are a significant public health concern.
What are the most serious complications to watch for in pediatric cannabinoid poisoning?
The most concerning complications include respiratory depression and cardiovascular effects like hypotension. Hemp-derived cannabinoid exposures specifically showed higher rates of these life-threatening complications, with some children requiring vasopressor medications to maintain blood pressure.
Should I treat hemp-derived cannabinoid exposures differently than traditional marijuana exposures?
Yes, clinicians should be prepared for potentially more severe presentations with hemp-derived cannabinoids. Given the higher rates of respiratory depression and hypotension, these patients may require more intensive monitoring and supportive care compared to traditional Delta-9 THC exposures.
What makes hemp-derived cannabinoids potentially more toxic than Delta-9 THC?
While the exact mechanism isn’t fully understood, hemp-derived cannabinoids like Δ8-THC, Δ10-THC, and THC-O may have different pharmacological properties than Delta-9 THC. The manufacturing processes and potential contaminants in these newer synthetic cannabinoids could also contribute to their increased toxicity profile in pediatric patients.
